Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches

Mechanisms of Resistance to KRASG12C Inhibitors

(2021) Victoria Dunnett-Kane et al.   Cancers

The Frequency of Ras Mutations in Cancer

(2020) Ian A. Prior et al.   CANCER RESEARCH

Targeting KRAS G12C ‐mutant cancer with a mutation‐specific inhibitor

(2020) James G. Christensen et al.   JOURNAL OF INTERNAL MEDICINE

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS

(2020) Nicolas Bery et al.   Nature Communications

1279P Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC)

(2020) J. Mazieres et al.   ANNALS OF ONCOLOGY

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

(2020) David S. Hong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

(2020) Yi-Long Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition

(2020) Marco H Hofmann et al.   Cancer Discovery

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition

(2019) Helen Adderley et al.   EBioMedicine

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction

(2019) Roman C. Hillig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

(2019) Wenting Liao et al.   CANCER CELL

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

(2019) Matthias Scheffler et al.   Journal of Thoracic Oncology

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes

(2019) Jacqueline V. Aredo et al.   LUNG CANCER

SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells

(2019) Lei Jiang et al.   Artificial Cells Nanomedicine and Biotechnology

LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042

(2019) R S Herbst et al.   ANNALS OF ONCOLOGY

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

(2019) Jill Hallin et al.   Cancer Discovery

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

(2019) David E. Gerber et al.   LUNG CANCER

Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors

(2019) Patrícia Dias Carvalho et al.   Cancers

Correlation between Programmed Death-1 Ligand-1 and p53 in Patients with Lung Adenocarcinoma

(2018) Zhi-Hong Zhang et al.   CHINESE MEDICAL JOURNAL

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

(2018) Ferdinandos Skoulidis et al.   Cancer Discovery

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer

(2017) Pasi A. Jänne et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

(2016) S. Koyama et al.   CANCER RESEARCH

LKB1 loss links serine metabolism to DNA methylation and tumorigenesis

(2016) Filippos Kottakis et al.   NATURE

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

(2016) Joshua D Campbell et al.   NATURE GENETICS

Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design

(2016) Jonathan M. L. Ostrem et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer

(2016) P. Tomasini et al.   ONCOLOGIST

Current status of the development of Ras inhibitors

(2015) Fumi Shima et al.   JOURNAL OF BIOCHEMISTRY

Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

(2015) F. Skoulidis et al.   Cancer Discovery

KRAS Protein Stability Is Regulated through SMURF2: UBCH5 Complex-Mediated β-TrCP1 Degradation

(2015) Shirish Shukla et al.   NEOPLASIA

The prognostic and predictive value ofKRASoncogene substitutions in lung adenocarcinoma

(2013) Liza C. Villaruz et al.   CANCER

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer

(2013) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer

(2013) Petra Martin et al.   Journal of Thoracic Oncology

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

(2013) Jonathan M. Ostrem et al.   NATURE

In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction

(2013) F. Shima et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Comprehensive Survey of Ras Mutations in Cancer

(2012) I. A. Prior et al.   CANCER RESEARCH

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

(2012) S. Dogan et al.   CLINICAL CANCER RESEARCH

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

(2012) Pasi A Jänne et al.   LANCET ONCOLOGY

Analysis of Binding Site Hot Spots on the Surface of Ras GTPase

(2011) Greg Buhrman et al.   JOURNAL OF MOLECULAR BIOLOGY

A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

(2011) Gregory J. Riely et al.   Journal of Thoracic Oncology

Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non-Small Cell Lung Cancer Cell Lines

(2010) E. B. Garon et al.   MOLECULAR CANCER THERAPEUTICS

Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells

(2009) Junichi Soh et al.   PLoS One